Skip to main content

Table 2 Complications and prognosis of all patients between MSD and AD

From: Alternative donor peripheral blood stem cell transplantation for the treatment of high-risk refractory and/or relapsed childhood acute leukemia: a randomized trial

Variables MSD (n = 42) AD (n = 69) χ2 P-value
Acute GVHD (n, %) 0.435 0.509
 Yes 15 (35.7) 29 (42.0)
 No 27 (64.3) 40 (58.0)
Grade II-IV aGVHD (n, %) 3.788 0.052
 Yes 2 (4.8) 12 (17.4)
 No 40 (95.2) 57 (82.6)
Chronic GVHD (n, %) 0.046 0.83
 Yes 9 (21.4) 16 (23.2)
 No 33 (78.6) 53 (76.8)
IPFD (n, %) 0.274 0.601
 Yes 12 (28.6) 23 (33.3)
 No 30 (71.4) 46 (66.7)
Hemorrhagic cystitis (n, %) 3.690 0.055
 Yes 8 (19.0) 25 (36.2)
 No 34 (81.0) 44 (63.8)
EBV infection (n, %) 17.674 < 0.001
 Yes 1 (2.4) 26 (37.7)
 No 41 (97.6) 43 (62.3)
CMV infection (n, %) 13.100 < 0.001
 Yes 9 (21.4) 39 (56.5)
 No 33 (78.6) 30 (43.5)
Relapse (n, %) 5.056 0.025
 Yes 19 (45.2) 17 (24.6)
 No 23 (54.8) 52 (75.4)
Death (n, %) 4.197 0.041
 Yes 16 (38.1) 14 (20.3)
 No 26 (61.9) 55 (79.7)
Non-relapse mortality (n, %) 4.051 0.044
 Yes 1 (6.3)* 5 (35.7)*
 No 15 (93.4)* 9 (64.3)*
  1. GVHD graft-versus-host disease, IPFD Invasive pulmonary fungal disease, EBV Epstein-Barr virus, CMV Cytomegalovirus; *Non-relapse mortality and relapse mortality as a percentage of total deaths